Alkem Laboratories Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/v9iqwknv21hpibjus4kxot1h.pdf

Key Takeaways


India Business: The Growth Engine

Sandeep Singh: "Price is a big lever this year, around 7%."

US Business: Price Erosion Easing, Launches Filling the Gap

Sandeep Singh: "The entire FY22 was depressed compared to FY21, so as you can see we have degrown by 5% in the current year, so if I am basically guiding them to 12% increase over FY22, in fact we are only guiding for 7% increase over FY21."

Margin Walk: The Raw Material Overhang

Rajesh Dubey: "So, one good thing now, this material prices, it has started showing softening trend and that good thing happening, but whatever material we have procured, ultimately we are going to consume it..."

Biosimilars (Enzene): Investment Phase, Distant Payoff


Chronic Portfolio: The Next Leg

Yogesh Koushal: "Right now, we should be ... around ₹1,000 to ₹2,000 crores in 3 to 4 years' time."

Capital Allocation & Strategy: Conservative, Focused

Sandeep Singh: "We continue to be the same, DNA has not changed, we are conservative, we will do what know to do best and so no large acquisition plans Prakash bhai."

Guidance & Commitments

CommitmentSpecificsTimeline
India revenue growthDouble-digit growth in FY23FY23
India growth splitPrice ~6–7%, new introductions ~3%, volume 3–5%FY23
US revenue growth10–12% YoY growthFY23
US price erosionHigher single digits (vs ~11–12% in FY22)FY23
Other international markets growthDouble-digit growth sustainedFY23
Gross margin59–60% (down from normal 61–62%), a 100–150 bps impactFY23
EBITDA margin~18% (down from 19.3% in FY22), a 150–175 bps hitFY23
Gross margin recoveryBack to 60–61% levelsFY24 onwards
EBITDA margin trajectory50–100 bps decline in FY23, then hopefully going upFY23, then recovery
R&D spend5.5% to 6% of salesFY23
Biosimilars revenue~₹250 croresFY23
Biosimilars US filing (Denosumab)Filing around end-2024End-2024
Biosimilars regulated-market launchBig growth when launched in US and Europe3–4 years away
Chronic portfolio scale₹1,000–2,000 crores3–4 years
Tax rate11% to 14%Next 2 years (until ~FY26–27)

Key Metrics

MetricQ4 FY22
Revenue from operations13.3% YoY growth
India business revenue growth16.7% YoY
US business revenue growthAlmost flat YoY
Other international business revenue growth35.3% YoY
EBITDA margin13.6%
Full-year EBITDA margin19.3%
Full-year gross margin60.7%, positive 20 bps addition YoY
India business share of total sales70% for FY22, up from 65% in FY21
US business full-year sales$318 million, down 4% YoY
US price erosion, full-year11–12% (lower double digits)
US price erosion guidance for FY23Higher single digits
US revenue growth guidance for FY2310–12%
ANDAs filed with US FDA during the year14 filed, 21 approvals received
Total ANDAs filed with US FDAOver 160, nearly half yet to be commercialized
ANDAs currently selling in the USAbout 85, roughly 15 yet to reach full potential
India branded business split85% acute, 15% chronic
Trade generic share of India business22%
India price increase expected for FY236–7%
India new introduction contribution expected~3%
India volume growth expected3–5%
India market share gain vs IPM0.3% increase
Total medical representative count10,000, split 17% chronic and rest acute
MR productivity, acute~₹6 lakhs PCPM
MR productivity, chronic₹3–3.25 lakhs PCPM
MR additions in Q4 FY22500 people added
R&D spend as percentage of sales~6.4% in Q4; FY23 guidance 5.5–6%
R&D spend allocation to US~90%
Biosimilars revenue expectation for next year~₹250 crores
Biosimilars investment to date~₹750 crores
Biosimilars annual R&D investment going forward~₹100 crores per year
Enzene negative EBITDA contribution~₹100 crores last year
Tax rate guidance for next 2 years11–14%
FY23 EBITDA margin expectation~18%, reflecting 150–175 bps hit from input costs
FY23 gross margin expectation59–60%, down 100–150 bps from FY22
Q4 gross margin impact from high raw material cost1.6–1.7%
Q4 gross margin impact from US price erosion~1.7%
US contribution to total revenueMore than 25%
Chronic portfolio size relative to acuteAround one third of acute
Domestic business growth expectation for FY23~13% overall, acute 10–11%, chronic ~20%